TBPH R&D to Revenue
Theravance Biopharma Inc · R&D to Revenue
TBPH R&D to Revenue
Latest reported34.82%period ending
TBPH FY R&D/Revenue (665.48% → 34.82%)
Latest values, visible window
High-resolution chart · PNG
TBPH r&d to revenue history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 34.8154% | |
| 59.1013% | |
| 80.7049% | |
| 136.4741% | |
| 364.3904% | |
| 363.156% | |
| 298.646% | |
| 333.5233% | |
| 1,130.1638% | |
| 291.3008% | |
| 306.6159% | |
| 1,441.8378% | |
| 53,353.5398% | |
| 87.5908% | |
| 665.4773% |